Likewise, we showed that the chemically modified monomeric compound LHD could bind to FTO and interfere with the FTO-mediated m6A modification, thereby ameliorating the hyperlipidemia- and PA-induced inflammatory responses in cardiomyocytes. The gene discussed is FTO; the disease is hyperlipidemia.